Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
QURE - uniQure N.V.
Market Cap 478.70M P/E - EPS this Y 34.30% Ern Qtrly Grth -
Income -284.69M Forward P/E -2.24 EPS next Y 34.60% 50D Avg Chg -30.00%
Sales 27.71M PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book 1.36 EPS next 5Y - 52W High Chg -64.00%
Recommedations 2.00 Quick Ratio 6.62 Shares Outstanding 48.70M 52W Low Chg 8.00%
Insider Own 4.33% ROA -17.12% Shares Float 37.99M Beta 0.95
Inst Own 72.14% ROE -126.41% Shares Shorted/Prior 4.27M/4.31M Price 10.06
Gross Margin - Profit Margin - Avg. Volume 917,950 Target Price 19.18
Oper. Margin -425.99% Earnings Date Aug 1 Volume 1,168,323 Change -5.27%
Healthcare | Biotechnology | Netherlands
About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V. News
12/17/24 uniQure price target raised to $32 from $12 at Stifel
12/15/24 Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
12/11/24 QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
12/11/24 Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
12/10/24 UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
12/10/24 UniQure shares soar on chance of speedy approval for Huntington’s therapy
12/10/24 uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
12/07/24 Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?
11/29/24 Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
11/28/24 What Makes uniQure (QURE) a New Buy Stock
11/21/24 uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
11/08/24 Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
11/07/24 What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates
11/06/24 uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
11/05/24 UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
11/05/24 UniQure: Q3 Earnings Snapshot
11/05/24 uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
10/30/24 Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
10/29/24 UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
10/15/24 uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Dolmetsch Ricardo President, R&D President, R&D Sep 18 Sell 7.46 5,841 43,574 163,404 09/20/23
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jul 10 Sell 11.36 15,117 171,729 95,098 07/12/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Mar 07 Sell 21.36 585 12,496 90,381 03/09/23
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Option 5.31 37,762 200,516 122,554 07/29/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jul 27 Sell 25 37,762 944,050 95,196 07/29/22
CALOZ PIERRE Chief Operating Offi.. Chief Operating Officer Jun 16 Sell 13.21 7,575 100,066 64,511 06/21/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jun 16 Sell 13.20 1,687 22,268 104,688 06/21/22
POST LEONARD E Director Director Feb 28 Sell 16.64 795 13,229 3,121 03/02/22
Kaye Jack Director Director Feb 28 Sell 16.76 600 10,056 19,003 03/02/22
Springhorn Jeremy P. Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Meek David D. Director Director Feb 28 Sell 16.7 602 10,053 7,380 03/02/22
Balachandran Madhavan Director Director Feb 28 Sell 16.7 602 10,053 10,877 03/02/22
Soteropoulos Paula Director Director Feb 28 Sell 16.87 596 10,055 7,302 03/02/22
Dolmetsch Ricardo President, R&D President, R&D Feb 28 Sell 16.68 1,484 24,753 122,325 03/02/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.8 4,075 68,460 106,375 03/02/22
Gut Robert Director Director Jan 26 Sell 18.12 2,348 42,546 35,153 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Jan 26 Sell 18.02 2,945 53,069 63,697 01/28/22
KLEMT CHRISTIAN Chief Financial Offi.. Chief Financial Officer Jan 26 Sell 18.03 3,963 71,453 66,820 01/28/22
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Jan 26 Sell 18.1 10,901 197,308 245,676 01/28/22
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Option 5.31 6,000 31,860 72,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Dec 15 Sell 27.9 6,000 167,400 66,642 12/15/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Sell 36.32 6,000 217,920 68,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations Sep 16 Option 5.31 6,000 31,860 74,871 09/16/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Option 5.31 6,000 31,860 74,871 05/18/21
Kuta Alexander Edward III Executive VP, Operat.. Executive VP, Operations May 18 Sell 31.66 6,000 189,960 68,871 05/18/21
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Dec 21 Option 7.53 12,501 94,133 277,738 12/21/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Option 7.53 3,216 24,216 283,780 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Nov 20 Sell 43.93 10,313 453,050 273,467 11/20/20
Kapusta Matthew C CEO, CFO, Managing D.. CEO, CFO, Managing Director Sep 18 Sell 41.28 7,500 309,600 285,814 09/18/20